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Abstract
Purpose: Soft tissue sarcomas (STS) account for less than 1% of all malignancies and constitute a heterogeneous tumor
entity in which malignant fibrous histiocytomas (MFH) represent one-third and are characterized by a lack of type-specific
differentiation. A defective mismatch repair (MMR) system cause the familial cancer syndrome hereditary non-polyposis
colorectal cancer (HNPCC), and since occasional MFH have been described in HNPCC patients we assessed the
contribution of defective MMR to the development of MFH.
Methods: MMR status was characterized in a series of 209 histopathologically reviewed MFH. Tissue microarray sections
from the tumors were immunohistochemically stained for the MMR proteins MLH1, MSH2 and MSH6, and cases with
aberrant staining were further characterized for microsatellite instability.
Results and Discussion: Two of the 209 STS – a storiform-pleomorphic MFH and a myxofibrosarcoma – showed
concomitant loss of MSH2 and MSH6, but retained staining for MLH1 on both cases. The myxoid tumor also had a
microsatellite unstable phenotype. These findings, together with previous observations of defective MMR in pleomorphic
STS, indicate that these tumors may be part of the HNPCC-associated tumor spectrum and demonstrate that MMR defects
occur in a small subset of STS.
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Introduction
Soft tissue sarcomas (STS) are rare with an
incidence of 20–25 per million. There are more
than 50 histological subtypes of STS, and with
increased use of ancillary techniques, such as
electron microscopy and immunohistochemical
staining, a line of differentiation can be identified
in most STS. This development has had particular
consequences for malignant fibrous histiocytoma
(MFH). MFH was introduced as a specific STS
subentity, with fibroblastic appearance but of pro-
posed histiocytic origin, during the 1960s.
1 MFH
quickly became the most common STS entity, with
the two most common subtypes being the pleo-
morphic-storiform and the myxoid types.
2 Since its
introduction, there has been intense debate among
pathologists with a special interest in STS regarding
the histogenesis, or line of differentiation shown by
MFH and many of these tumors show heterogeneous
morphology and multiple, often complex, cytoge-
netic aberrations.
2,3
Hereditarynonpolyposiscolorectalcancer(HNPC-
C) is an autosomal dominant inherited disorder that
affects 1/1000–2000 individuals.
4,5 HNPCC predis-
poses for several tumor types, with the greatest
life-time risks for colorectal cancer (70–90%),
endometrial cancer (40–60%), and increased risks
also for cancer of the ovary, ventricle, small intestine,
hepatobiliary tract, upper urothelial tract, skin and
brain.
6 Clinical criteria, the Amsterdam II criteria,
for the classification of HNPCC have been estab-
lished and include tumor development in at least
three individuals in two generations and with one
individual diagnosed before age 50. The Amsterdam
II criteria consider carcinomas of the colon, rectum,
endometrium, small intestine and upper urothelial
tract to be closely associated with HNPCC.
7
HNPCC is characterized by a defective mismatch
repair (MMR) system, which normally eliminates
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that arise as a consequence of DNA polymerase
slippage during DNA replication. HNPCC is caused
by MMR gene mutations, with 90% of the mutations
affecting the genes MLH1, MSH2, and MSH6.
8,9
Failure to repair DNA mismatches generates small
insertion/deletion mutations, which in the tumor
tissue appear as altered lengths of small tandem
repeats, referred to as microsatellite instability (MSI)
and loss of the immunohistochemical expression of
the affected MMR protein.
8,10
A role for defective MMR has been suggested in
sarcoma development through observations of occa-
sional sarcomas in HNPCC families and through
reports of MMR defects in a subset of STS.
11–15 We
therefore applied tissue microarray (TMA) to study
the expression of the MMR proteins MLH1, MSH2
and MSH6 in a series of 209 MFH in order to
determine a possible contribution of MMR defects
in MFH tumorigenesis.
Material and methods
Material
The Scandinavian Sarcoma Group (SSG) has since
1986 maintained a sarcoma registry, which contains
approximately 90% of all diagnosed STS of the
extremities and trunk wall. The 209 tumors studied
herein have been re-evaluated by the SSG Pathology
Review Group (10 Scandinavian pathologists)
with access to the clinical history and previous
pathology reports. When necessary, electron micro-
scopy and extensive immunohistochemical stainings
were performed to exclude a demonstrable lineage
of differentiation.
16 The antibody panel included
muscle specific actin, smooth muscle actin, desmin,
S-100, epithelial membrane antigene, EMA, cyto-
keratin and several markers specific for melanoma
and lymphoma. Malignancy grading was based on
a IV-tiered grading system, including the factors
cellularity, pleomorphism, nuclear atypia, tumor
necrosis, vascular invasion and mitotic activity. The
IV-tiered grading system is used by the SSG
Pathology Review Group.
25
Tumor-containing, paraffin-embedded tissue
blocks were selected. Core biopsies with a diameter
of 0.6mm were retrieved from the original
tumor blocks using a manual analyzer (Beecher
Instruments, USA) and were positioned in a
recipient paraffin array block. Between three and
nine core biopsies were studied from each tumor.
The TMA slides were immunostained using
antibodies to the MMR proteins MLH1, MSH2
and MSH6 (see below). Tumors that showed
inconclusive staining or suspected expression
loss in the TMA sections were further immuno-
stained using whole-tissue sections in order to
confirm the results. The two tumors that showed
loss of the MMR proteins were also subjected to
MSI analysis. Ethical approval for the study
was obtained from the ethics committee at Lund
University.
Immunohistochemistry
Immunohistochemical staining was performed using
4-mm sections of formalin-fixed, paraffin-embedded
tissue, which were mounted on DAKO ChemMate
Capillary Gap Microscope Slides (DAKO A/S
BioTek Solutions, USA) and dried at room tem-
perature overnight followed by 1–2h at 60 C. The
tissue sections were deparaffinized and rehydrated.
Antigen retrieval was achieved by microwave-
treatment in 1 mM EDTA, pH 9.0, at 900W for
8min followed by 15min at 350 W. The slides were
then allowed to cool for at least 20min in the
EDTA solution. Primary antibodies were mouse
monoclonal IgG antibodies to MLH1 (clone G168–
15, dilution 1:100, PharMingen, San Diego, CA,
USA), MSH2 (clone FE-11, dilution 1:100,
Oncogene Research Products, Boston, MA, USA)
and MSH6 (clone 44, dilution 1:1000, BD
Transduction Laboratories). Immunohistochemical
staining was performed in an automated immuno-
stainer (TechMate
TM 500 Plus, DAKO), according
to the manufacturers instructions. DAKO
ChemMate Kit peroxidase/3,3
0-diaminobenzidine
was used for MLH1 and MSH2 and DAKO
Envision
TM/HRP rabbit/mouse for MSH6, with
rabbit anti-mouse IgG, dilution 1:400, as a link to
amplify between the primary antibody and the
Envision step. Diaminobenzidine was used as a
chromogen. The sections were counterstained with
hematoxylin, dehydrated in ascending concentra-
tions of alcohol to xylene and mounted. A detailed
protocol is available from the authors on request.
Tumors from HNPCC patients with known germ-
line mutations in MSH2, MLH1 and MSH6,
respectively, served as controls in each staining
round. Loss of expression of the respective MMR
protein was defined as absence of nuclear staining in
the tumor cells, and normal nuclear staining in
lymphocytes and normal epithelial or stromal cells
was required serving as internal control (Fig. 1).
The expression was classified as present, absent
or non-evaluable without grading of the staining
intensity.
MSI analysis
DNA was extracted from 3 10-mm sections
of formaldehyde-fixed, paraffin-embedded tissue
through incubation of the samples in EDTA–Tris
buffer with Proteinase K (at 65 C for at least 2h,
followed by boiling, centrifugation, and removal of
the aqueous phase, which was stored at 4 C). The
124 K. Ericson et al.MSI status of the tumors was established using the
MSI Multiplex System Prototype Kit (Promega,
USA) and with the markers BAT25, BAT26,
BAT34C4, D2S123 and D5S346. Data from at
least three of the markers were required. The MSI
markers used herein have been shown to assess MSI
with high accuracy.
17 Details on fluorescent labelling
and PCR conditions for the different markers can be
obtained from the authors on request. The PCR
products were mixed with 12ml deionized formamide
(Hi-Di Formamide, Applied Biosystems) and 0.5ml
ROX
TM 500 Size Standard (Applied Biosystems),
denatured at 95 C for 2min, and separated in
Performance Optimized Polymer-4 (POP-4
TM)o n
an ABI PRISM
TM 3100 Genetic Analyzer (Applied
Biosystems).
Results
Of the 209 MFH, 25 tumors showed weak or
inconclusive immunostaining. These tumors were
further stained using whole-tissue sections.
Thereafter, 202 tumors were determined to have
normal retained immunostaining for all three anti-
bodies, two tumors showed loss of expression for
MSH2 and MSH6, with retained staining for
MLH1, and five tumors were non-evaluable due to
poor staining quality or lack of staining in the
internal control. The two tumors with loss of
MSH2 and MSH6 were both high-grade MFH
(Fig. 1). The 20-cm storiform-pleomorphic MFH
developed in the left thigh of a 96-year-old woman.
The tumor was multinodulated and showed a
cellular stroma with central necrotic areas and
pleomorphic cells with hyperchromatic nuclei and
prominent nucleoli. The myxofibrosarcoma was a 7-
cm tumor that developed in the right biceps muscle
in 77-year-old man. The tumor showed a myxoid
stroma with variable cellularity and elongated blood
vessels and the fusiform tumor cells showed atypical,
enlarged and hyperchromatic nuclei. MSI analysis
showed MSI for the markers NR21 and D5S346
in the myxoid MFH, whereas the storiform-
pleomorphic MFH did not show MSI for the
markers analysed.
Discussion
We identified loss of MSH2/MSH6 in 2/209 STS
and both tumors were high-grade tumor that
developed in elderly patients (Fig. 1). The stori-
form-pleomorphic MFH developed in a woman who
is now deceased, but who had not previously been
affected by cancer. However, both her father and
her brother died from rectal cancer in their seventies,
but their tumors were not available for analysis.
The myxoid MFH developed in a man who had
previously been diagnosed with a prostate cancer,
and is now deceased. A family history of cancer was
not possible to obtain since he was of non-
Scandinavian origin and had no offspring. STS
have been associated with several hereditary syn-
dromes that confer an increased risk of cancer,
including Werner syndrome due to mutations in
the WRN gene, Li-Fraumeni syndrome due to
germline TP53 mutations, and other rare syndromes
such as Rothmund–Thomson syndrome and Bloom
syndrome.
11,18–20
HNPCC is estimated to occur at a population
frequency of 1/1000–2000 and predisposes to a wide
spectrum of tumors, including colorectal cancer,
endometrial cancer, cancer of the ovary, ventricle,
small intestine, hepatobiliary tract, upper urinary
tract, skin, and brain.
6 Sarcomas are generally not
considered to occur in the context of HNPCC,
MLH1
a)
MSH2 MSH6
b)
Fig. 1. Loss of immunohistochemical expression of MSH2 and MSH6, with retained expression of MLH1 in
a storiform-pleomorphic MFH (a) and a myxoid MFH (b).
MSH2 and MSH6 in malignant fibrous histiocytomas 125but have been reported to occur in 1–2% of HNPCC
patients.
21,22 Sarcoma development in HNPCC
patients have been reported in four case reports,
and included three MFH and a pleomorphic
rhabdomyosarcoma.
11,13,14,21 The two tumors that
were genetically investigated (one MFH and the
rhabdomyosarcoma) showed MSI and
immunohistochemical loss of MSH2 expression.
Our findings, together with the previous reports of
MMR-defective sarcomas with loss of MSH2,
demonstrate that sarcomas may represent a rare
tumor type in HNPCC families. So far, the sarcomas
have specifically been associated with inactivation of
MSH2/MSH6, and a higher risk of extraintestinal
tumors have indeed been described in HNPCC
families with mutations affecting the MSH2 gene.
23
Since MSH2 and MSH6 functionally interact, a
simultaneous loss of both proteins is expected.
24
Loss of MSH2 expression has so far exclusively been
associated with germline mutations in colorectal
cancer. However, somatic mutations could occur in
other tumor types.
The possible role for defective MMR in the
development of non-HNPCC-associated STS is
unclear. Our study does not indicate that defective
MMR should be a major tumorigenic mechanism in
these tumors. However, Suwa et al. found MSI in
three of 39 STS (a liposarcoma, a synovial sarcoma
and a leiomyosarcoma),
15 and Saito et al. reported a
MSI low phenotype and loss of MLH1/MSH2
expression in five of 11 alveolar soft part sarcomas
(ASPS).
12 Perhaps different genetic mechanisms
apply, with the MSI-high tumors representing only
the small fraction of the STS that are associated with
HNPCC, whereas a larger subset of STS may display
instability at a single loci and thus be of the MSI-low
phenotype.
In summary, a subset of STS develop through
defective MMR, and MFH may occur as a rare
tumor within the HNPCC tumor spectrum. This
implicates that HNPCC testing may be performed in
family members who have developed STS and
suggests that genetic counseling should be offered
patients with STS who reveal a family history of
HNPCC-associated tumors.
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